Biogen and City Therapeutics Forge Strategic Partnership to Pioneer Next-Generation RNAi-Based Therapies Targeting Central Nervous System Diseases Biogen,a global leader in neuroscience and neurodegenerative disease research, and City Therapeutics, Inc., a private biopharmaceutical company at the forefront of RNA interference…
Merck Highlights Breakthrough Innovations in Advanced Cancers and Rare Tumors at ASCO 2025 Merck, a global leader in science and technology, has once again showcased its commitment to transforming cancer care through the presentation of groundbreaking clinical data across a…
AbbVie Gains First Solid Tumor FDA Approval With EMRELIS™ for High c-Met Overexpressing Advanced NSCLC AbbVie has achieved a key milestone in its oncology pipeline with the announcement that the U.S. Food and Drug Administration (FDA) has granted accelerated approval…
Feinstein Institutes Study Vagus Nerve Stimulation for Obesity Obesity is one of the most pressing health challenges facing the modern world, with over a third of the global population affected by excess weight. This complex and multifactorial condition contributes to…
Ten-Year Data Perjeta Regimen Cuts Death Risk by 17% in HER2+ Breast Cancer In a significant milestone for the treatment of early-stage HER2-positive breast cancer, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), together with the…
Azafaros Raises €132M in Series B to Advance Phase 3 LSD Therapies Azafaros, a clinical-stage biotechnology company with a specialized focus on rare lysosomal storage disorders (LSDs), announced the successful completion of a €132 million ($142 million USD equivalent) Series…
A global healthcare company today announced positive top-line results from its Phase 3 clinical trial (NCT05139121) evaluating the contraceptive efficacy and safety of XULANE LO, an investigational low-dose weekly transdermal patch delivering 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol…
AstraZeneca announced promising top-line results from its Phase III POTOMAC trial, showing that one year of treatment with Imfinzi (durvalumab) combined with standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly improved disease-free survival (DFS) for patients with high-risk non-muscle-invasive…
GSK Reports Positive Phase III Results for Linerixibat in Treating Itch Associated with PBC GSK plc (LSE/NYSE: GSK) today announced positive results from its GLISTEN phase III trial evaluating linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor, in adults…
90% of Adults with Chronic Hepatitis Delta Who Cleared Virus on Bulevirtide Stayed Clear Nearly 2 Years After Stopping Treatment Gilead Sciences, Inc. (Nasdaq: GILD) today announced final results from the Phase 3 MYR301 study showing that nearly 90% of…
Enhertu Plus THP Shows Improved Safety and Efficacy Over Standard of Care in Early HER2-Positive Breast CancerAstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), followed by a regimen of paclitaxel, trastuzumab, and pertuzumab (THP), has shown a significantly improved safety profile…
TREMFYA® Shows Sustained Long-Term Remission in Ulcerative Colitis Patients, According to Phase 3 QUASAR LTE Study More than 70% of patients in clinical remission and over 40% in endoscopic remission at Week 92 Johnson & Johnson (NYSE: JNJ) today announced…